XML 53 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Item
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
License And Collaboration Agreements [Line Items]                        
Revenue recognized related to upfront and milestone payments                 $ 4,382,000 $ 973,000    
Licenses revenue             $ 135,317,000 $ 100,792,000 290,310,000 174,070,000    
Deferred revenue             20,213,000 19,737,000 20,213,000 19,737,000 $ 20,846,000 $ 20,710,000
Product Revenue, Net                        
License And Collaboration Agreements [Line Items]                        
Licenses revenue             133,724,000 100,366,000 $ 285,928,000 173,097,000    
Mochida | In-licenses                        
License And Collaboration Agreements [Line Items]                        
Milestones payment   $ 1,000,000.0                    
Mochida | In-licenses | Research and Development Expense                        
License And Collaboration Agreements [Line Items]                        
Upfront payment                       $ 2,700,000
Eddingpharm | Out-licenses                        
License And Collaboration Agreements [Line Items]                        
Non-refundable up-front received           $ 15,000,000.0            
Number of indications of the regulatory milestone events relating to the submission and approval | Item                 3      
Amounts to be received upon achievement of the regulatory milestone events                 $ 33,000,000.0      
Sales-based milestone event payment                 120,000,000.0      
Revenue recognized related to upfront and milestone payments                 1,600,000      
Deferred revenue             11,300,000   11,300,000   13,000,000.0  
Eddingpharm | Out-licenses | Licensing Revenue                        
License And Collaboration Agreements [Line Items]                        
Licenses revenue                 4,600,000   3,000,000.0  
Eddingpharm | Out-licenses | Maximum                        
License And Collaboration Agreements [Line Items]                        
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                 153,000,000.0      
Amounts to be received upon achievement of the regulatory milestone events                 15,000,000.0      
Sales-based milestone event payment                 50,000,000.0      
Revenue recognized related to upfront and milestone payments                   100,000    
Eddingpharm | Out-licenses | Minimum                        
License And Collaboration Agreements [Line Items]                        
Amounts to be received upon achievement of the regulatory milestone events                 2,000,000.0      
Sales-based milestone event payment                 5,000,000.0      
Eddingpharm | Out-licenses | Clinical Trial Application                        
License And Collaboration Agreements [Line Items]                        
Non-refundable milestone payment         $ 1,000,000.0              
Biologix FZCo | Out-licenses                        
License And Collaboration Agreements [Line Items]                        
Revenue recognition period of non-refundable up-front payment         10 years              
Biologix FZCo | Out-licenses | Product Revenue, Net                        
License And Collaboration Agreements [Line Items]                        
Licenses revenue                   300,000    
HLS | Out-licenses                        
License And Collaboration Agreements [Line Items]                        
Non-refundable up-front received       $ 5,000,000.0                
Non-refundable milestone payment $ 2,500,000 $ 3,800,000 $ 2,500,000 $ 2,500,000                
Revenue recognized related to upfront and milestone payments                 2,700,000 800,000    
Deferred revenue             8,100,000   8,100,000   7,100,000  
Non-refundable up-front received period       6 months                
Non-refundable milestone payment received       $ 3,800,000                
HLS | Out-licenses | Health Canada                        
License And Collaboration Agreements [Line Items]                        
Non-refundable milestone payment       2,500,000                
HLS | Out-licenses | Licensing Revenue                        
License And Collaboration Agreements [Line Items]                        
Licenses revenue                 5,600,000   $ 2,900,000  
HLS | Out-licenses | Product Revenue, Net                        
License And Collaboration Agreements [Line Items]                        
Licenses revenue             $ 1,800,000 $ 0 $ 8,500,000 $ 0    
HLS | Out-licenses | Maximum                        
License And Collaboration Agreements [Line Items]                        
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone       $ 50,000,000.0